NCT07463846

A Study to Evaluate ALN-2232 in Participants With Obesity

A Phase 1/2, Randomized, Double-blind, Placebo-controlled, Study of the Safety, Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of ALN-2232 as Monotherapy and Co-initiated With Tirzepatide in Adult Participants With Obesity

• Status: Recruiting
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 156 (estimated)
• Sponsor: Alnylam Pharmaceuticals · Industry
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to: * evaluate the safety, tolerability, efficacy, pharmacokinetics (PK), and pharmacodynamics (PD) of single ascending doses of ALN-2232 in patients with obesity * evaluate the safety, tolerability, efficacy, PK, and PD of multiple doses of ALN-2232 in patients with obesity * evaluate the safety, tolerability, efficacy, PK, and PD of multiple doses of ALN-2232 co-initiated with tirzepatide in patients with obesity

Conditions

• Obesity

Interventions

Type	Name	Description
DRUG	ALN-2232	ALN-2232 will be administered subcutaneously (SC)
DRUG	Placebo	Placebo will be administered SC
DRUG	Tirzepatide	Tirzepatide will be administered SC

Timeline

• Start date: 2026-03-02
• Primary completion: 2028-02-01
• Completion: 2028-03-01
• First posted: 2026-03-11
• Last updated: 2026-03-11

Locations

1 site across 1 country: Canada